nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—Fibromyalgia—Hydrochlorothiazide—nephrolithiasis	0.049	0.0673	CcSEcCtD
Escitalopram—CHRM1—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.0252	0.0924	CbGpPWpGaD
Escitalopram—Shoulder pain—Hydrochlorothiazide—nephrolithiasis	0.0228	0.0313	CcSEcCtD
Escitalopram—Local swelling—Hydrochlorothiazide—nephrolithiasis	0.0176	0.0242	CcSEcCtD
Escitalopram—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.0133	0.0183	CcSEcCtD
Escitalopram—ADRA1A—Endothelin Pathways—ADCY10—nephrolithiasis	0.0132	0.0484	CbGpPWpGaD
Escitalopram—Trauma—Hydrochlorothiazide—nephrolithiasis	0.0129	0.0177	CcSEcCtD
Escitalopram—Sinus bradycardia—Hydrochlorothiazide—nephrolithiasis	0.0125	0.0172	CcSEcCtD
Escitalopram—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.0117	0.0161	CcSEcCtD
Escitalopram—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.011	0.0151	CcSEcCtD
Escitalopram—Toothache—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0139	CcSEcCtD
Escitalopram—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.00892	0.0123	CcSEcCtD
Escitalopram—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.00852	0.0117	CcSEcCtD
Escitalopram—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.0083	0.0114	CcSEcCtD
Escitalopram—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.00782	0.0108	CcSEcCtD
Escitalopram—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00782	0.0108	CcSEcCtD
Escitalopram—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00746	0.0103	CcSEcCtD
Escitalopram—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.00694	0.00954	CcSEcCtD
Escitalopram—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00685	0.00941	CcSEcCtD
Escitalopram—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.0068	0.00934	CcSEcCtD
Escitalopram—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00662	0.0091	CcSEcCtD
Escitalopram—Gout—Hydrochlorothiazide—nephrolithiasis	0.00658	0.00904	CcSEcCtD
Escitalopram—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00649	0.00892	CcSEcCtD
Escitalopram—HTR2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00644	0.0236	CbGpPWpGaD
Escitalopram—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00641	0.00881	CcSEcCtD
Escitalopram—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00625	0.00859	CcSEcCtD
Escitalopram—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00625	0.00859	CcSEcCtD
Escitalopram—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00622	0.00854	CcSEcCtD
Escitalopram—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00614	0.00844	CcSEcCtD
Escitalopram—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00596	0.0082	CcSEcCtD
Escitalopram—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00577	0.00792	CcSEcCtD
Escitalopram—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00563	0.0207	CbGpPWpGaD
Escitalopram—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00561	0.00771	CcSEcCtD
Escitalopram—HRH1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00558	0.0205	CbGpPWpGaD
Escitalopram—CHRM1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00556	0.0204	CbGpPWpGaD
Escitalopram—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00555	0.00763	CcSEcCtD
Escitalopram—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00555	0.00763	CcSEcCtD
Escitalopram—ADRA1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00547	0.0201	CbGpPWpGaD
Escitalopram—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00541	0.0199	CbGpPWpGaD
Escitalopram—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00523	0.0192	CbGpPWpGaD
Escitalopram—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00708	CcSEcCtD
Escitalopram—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00512	0.00704	CcSEcCtD
Escitalopram—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00508	0.00698	CcSEcCtD
Escitalopram—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00503	0.00691	CcSEcCtD
Escitalopram—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00498	0.0183	CbGpPWpGaD
Escitalopram—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00498	0.00685	CcSEcCtD
Escitalopram—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00494	0.00679	CcSEcCtD
Escitalopram—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00489	0.00672	CcSEcCtD
Escitalopram—Injury—Hydrochlorothiazide—nephrolithiasis	0.00485	0.00666	CcSEcCtD
Escitalopram—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00481	0.00661	CcSEcCtD
Escitalopram—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00477	0.00655	CcSEcCtD
Escitalopram—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00474	0.00652	CcSEcCtD
Escitalopram—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00472	0.00649	CcSEcCtD
Escitalopram—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0047	0.00646	CcSEcCtD
Escitalopram—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.0047	0.00646	CcSEcCtD
Escitalopram—HRH1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00469	0.0172	CbGpPWpGaD
Escitalopram—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00468	0.00644	CcSEcCtD
Escitalopram—CHRM1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00467	0.0172	CbGpPWpGaD
Escitalopram—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00463	0.017	CbGpPWpGaD
Escitalopram—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00462	0.00636	CcSEcCtD
Escitalopram—ADRA1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0046	0.0169	CbGpPWpGaD
Escitalopram—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00459	0.0063	CcSEcCtD
Escitalopram—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00448	0.00615	CcSEcCtD
Escitalopram—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00446	0.00613	CcSEcCtD
Escitalopram—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00446	0.00613	CcSEcCtD
Escitalopram—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00442	0.00608	CcSEcCtD
Escitalopram—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00439	0.00603	CcSEcCtD
Escitalopram—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00439	0.00603	CcSEcCtD
Escitalopram—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00439	0.0161	CbGpPWpGaD
Escitalopram—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.0043	0.00591	CcSEcCtD
Escitalopram—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00422	0.0058	CcSEcCtD
Escitalopram—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00419	0.00576	CcSEcCtD
Escitalopram—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00412	0.00566	CcSEcCtD
Escitalopram—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00409	0.00562	CcSEcCtD
Escitalopram—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00407	0.0056	CcSEcCtD
Escitalopram—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00407	0.0056	CcSEcCtD
Escitalopram—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00406	0.00558	CcSEcCtD
Escitalopram—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00403	0.00554	CcSEcCtD
Escitalopram—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00401	0.00552	CcSEcCtD
Escitalopram—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00401	0.00552	CcSEcCtD
Escitalopram—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00401	0.00552	CcSEcCtD
Escitalopram—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00395	0.00542	CcSEcCtD
Escitalopram—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00393	0.0054	CcSEcCtD
Escitalopram—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00393	0.0054	CcSEcCtD
Escitalopram—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00388	0.00533	CcSEcCtD
Escitalopram—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00385	0.00529	CcSEcCtD
Escitalopram—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00385	0.00529	CcSEcCtD
Escitalopram—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00378	0.00519	CcSEcCtD
Escitalopram—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00377	0.0138	CbGpPWpGaD
Escitalopram—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00375	0.00516	CcSEcCtD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00369	0.0135	CbGpPWpGaD
Escitalopram—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0036	0.00495	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00492	CcSEcCtD
Escitalopram—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00356	0.00489	CcSEcCtD
Escitalopram—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00355	0.00488	CcSEcCtD
Escitalopram—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00352	0.00483	CcSEcCtD
Escitalopram—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00351	0.00482	CcSEcCtD
Escitalopram—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00348	0.00478	CcSEcCtD
Escitalopram—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00346	0.00475	CcSEcCtD
Escitalopram—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00341	0.0125	CbGpPWpGaD
Escitalopram—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00341	0.00468	CcSEcCtD
Escitalopram—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00339	0.00465	CcSEcCtD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00337	0.0124	CbGpPWpGaD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00337	0.0124	CbGpPWpGaD
Escitalopram—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00337	0.00463	CcSEcCtD
Escitalopram—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00337	0.00463	CcSEcCtD
Escitalopram—ADRA1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00336	0.0123	CbGpPWpGaD
Escitalopram—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00335	0.0046	CcSEcCtD
Escitalopram—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.00334	0.0123	CbGpPWpGaD
Escitalopram—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00334	0.00459	CcSEcCtD
Escitalopram—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00334	0.00459	CcSEcCtD
Escitalopram—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00329	0.00453	CcSEcCtD
Escitalopram—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00328	0.0045	CcSEcCtD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00327	0.012	CbGpPWpGaD
Escitalopram—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00324	0.00445	CcSEcCtD
Escitalopram—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00322	0.00443	CcSEcCtD
Escitalopram—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00321	0.00441	CcSEcCtD
Escitalopram—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00314	0.00431	CcSEcCtD
Escitalopram—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00309	0.00425	CcSEcCtD
Escitalopram—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00308	0.00424	CcSEcCtD
Escitalopram—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00307	0.00422	CcSEcCtD
Escitalopram—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00306	0.00421	CcSEcCtD
Escitalopram—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00304	0.00417	CcSEcCtD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00299	0.011	CbGpPWpGaD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00299	0.011	CbGpPWpGaD
Escitalopram—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00297	0.00408	CcSEcCtD
Escitalopram—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00292	0.00401	CcSEcCtD
Escitalopram—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00395	CcSEcCtD
Escitalopram—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00286	0.00393	CcSEcCtD
Escitalopram—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00275	0.00379	CcSEcCtD
Escitalopram—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00273	0.00374	CcSEcCtD
Escitalopram—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00369	CcSEcCtD
Escitalopram—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00265	0.00364	CcSEcCtD
Escitalopram—Tension—Hydrochlorothiazide—nephrolithiasis	0.00263	0.00362	CcSEcCtD
Escitalopram—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00263	0.00361	CcSEcCtD
Escitalopram—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00358	CcSEcCtD
Escitalopram—Back pain—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00357	CcSEcCtD
Escitalopram—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00258	0.00355	CcSEcCtD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00256	0.00939	CbGpPWpGaD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00256	0.00939	CbGpPWpGaD
Escitalopram—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00348	CcSEcCtD
Escitalopram—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00252	0.00346	CcSEcCtD
Escitalopram—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00249	0.00342	CcSEcCtD
Escitalopram—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00248	0.00341	CcSEcCtD
Escitalopram—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00247	0.00339	CcSEcCtD
Escitalopram—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00337	CcSEcCtD
Escitalopram—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00242	0.00333	CcSEcCtD
Escitalopram—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00331	CcSEcCtD
Escitalopram—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00331	CcSEcCtD
Escitalopram—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.0024	0.0033	CcSEcCtD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00238	0.00873	CbGpPWpGaD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00238	0.00873	CbGpPWpGaD
Escitalopram—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00237	0.00326	CcSEcCtD
Escitalopram—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00236	0.00324	CcSEcCtD
Escitalopram—Cough—Hydrochlorothiazide—nephrolithiasis	0.00234	0.00322	CcSEcCtD
Escitalopram—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00314	CcSEcCtD
Escitalopram—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00314	CcSEcCtD
Escitalopram—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00314	CcSEcCtD
Escitalopram—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00228	0.00313	CcSEcCtD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00227	0.00832	CbGpPWpGaD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00227	0.00832	CbGpPWpGaD
Escitalopram—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00226	0.0031	CcSEcCtD
Escitalopram—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00224	0.00307	CcSEcCtD
Escitalopram—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00222	0.00816	CbGpPWpGaD
Escitalopram—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00221	0.00304	CcSEcCtD
Escitalopram—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00219	0.00301	CcSEcCtD
Escitalopram—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00219	0.00301	CcSEcCtD
Escitalopram—Shock—Hydrochlorothiazide—nephrolithiasis	0.00216	0.00296	CcSEcCtD
Escitalopram—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00215	0.00295	CcSEcCtD
Escitalopram—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00294	CcSEcCtD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00212	0.00778	CbGpPWpGaD
Escitalopram—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00212	0.00291	CcSEcCtD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00211	0.00773	CbGpPWpGaD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00211	0.00773	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0021	0.00772	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0021	0.00772	CbGpPWpGaD
Escitalopram—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00209	0.00287	CcSEcCtD
Escitalopram—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00281	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.002	0.00274	CcSEcCtD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00199	0.0073	CbGpPWpGaD
Escitalopram—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00198	0.00272	CcSEcCtD
Escitalopram—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00197	0.0027	CcSEcCtD
Escitalopram—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00195	0.00268	CcSEcCtD
Escitalopram—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00195	0.00268	CcSEcCtD
Escitalopram—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00193	0.00265	CcSEcCtD
Escitalopram—HRH1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00193	0.00707	CbGpPWpGaD
Escitalopram—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00192	0.00705	CbGpPWpGaD
Escitalopram—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.0019	0.00262	CcSEcCtD
Escitalopram—ADRA1A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00189	0.00694	CbGpPWpGaD
Escitalopram—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00189	0.0026	CcSEcCtD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00188	0.00689	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00187	0.00688	CbGpPWpGaD
Escitalopram—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00187	0.00257	CcSEcCtD
Escitalopram—Pain—Hydrochlorothiazide—nephrolithiasis	0.00187	0.00257	CcSEcCtD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00186	0.00684	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00186	0.00684	CbGpPWpGaD
Escitalopram—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00181	0.00248	CcSEcCtD
Escitalopram—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00179	0.00246	CcSEcCtD
Escitalopram—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00239	CcSEcCtD
Escitalopram—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00173	0.00238	CcSEcCtD
Escitalopram—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00173	0.00238	CcSEcCtD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00172	0.00633	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00172	0.00631	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00171	0.0063	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00171	0.0063	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00169	0.00621	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00166	0.00611	CbGpPWpGaD
Escitalopram—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00166	0.00611	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00166	0.0061	CbGpPWpGaD
Escitalopram—ADRA1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00164	0.00602	CbGpPWpGaD
Escitalopram—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00161	0.00222	CcSEcCtD
Escitalopram—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00161	0.0059	CbGpPWpGaD
Escitalopram—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00157	0.00216	CcSEcCtD
Escitalopram—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00155	0.00213	CcSEcCtD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00152	0.00558	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00152	0.00558	CbGpPWpGaD
Escitalopram—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.0015	0.00206	CcSEcCtD
Escitalopram—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.00149	0.00548	CbGpPWpGaD
Escitalopram—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00145	0.00199	CcSEcCtD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00144	0.00528	CbGpPWpGaD
Escitalopram—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00139	0.00191	CcSEcCtD
Escitalopram—HRH1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00139	0.00511	CbGpPWpGaD
Escitalopram—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00139	0.0051	CbGpPWpGaD
Escitalopram—Rash—Hydrochlorothiazide—nephrolithiasis	0.00138	0.0019	CcSEcCtD
Escitalopram—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00138	0.0019	CcSEcCtD
Escitalopram—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00137	0.00504	CbGpPWpGaD
Escitalopram—Headache—Hydrochlorothiazide—nephrolithiasis	0.00137	0.00189	CcSEcCtD
Escitalopram—ADRA1A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00137	0.00502	CbGpPWpGaD
Escitalopram—Nausea—Hydrochlorothiazide—nephrolithiasis	0.0013	0.00179	CcSEcCtD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.0013	0.00477	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.0013	0.00477	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00125	0.00457	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00124	0.00456	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00124	0.00456	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00122	0.00449	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00121	0.00444	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00121	0.00444	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00115	0.00423	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00115	0.00423	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00108	0.00395	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00108	0.00395	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00108	0.00395	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00107	0.00394	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00107	0.00393	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00107	0.00393	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00106	0.00391	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00106	0.00388	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000954	0.0035	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000954	0.0035	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.000938	0.00344	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000922	0.00339	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000919	0.00338	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000905	0.00332	CbGpPWpGaD
Escitalopram—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000898	0.0033	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000861	0.00316	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	0.000852	0.00313	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000813	0.00298	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.000811	0.00298	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00081	0.00297	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000798	0.00293	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000762	0.0028	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	0.000741	0.00272	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—RGS14—nephrolithiasis	0.000738	0.00271	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.000736	0.0027	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—RGS14—nephrolithiasis	0.000724	0.00266	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000702	0.00258	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.0007	0.00257	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000689	0.00253	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—PTH—nephrolithiasis	0.000642	0.00236	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	0.00064	0.00235	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.000634	0.00233	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—PTH—nephrolithiasis	0.00063	0.00231	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000592	0.00217	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	0.000575	0.00211	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000549	0.00202	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000547	0.00201	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000539	0.00198	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ADCY10—nephrolithiasis	0.000513	0.00188	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	0.000511	0.00188	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ADCY10—nephrolithiasis	0.000503	0.00185	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	0.000503	0.00185	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DGKH—nephrolithiasis	0.000499	0.00183	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	0.000497	0.00182	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DGKH—nephrolithiasis	0.000489	0.0018	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000458	0.00168	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RGS14—nephrolithiasis	0.000436	0.0016	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	0.000435	0.0016	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RGS14—nephrolithiasis	0.000428	0.00157	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	0.000419	0.00154	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000416	0.00153	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000397	0.00146	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000396	0.00145	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000389	0.00143	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	0.00038	0.0014	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PTH—nephrolithiasis	0.000363	0.00133	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	0.000362	0.00133	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00036	0.00132	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000359	0.00132	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PTH—nephrolithiasis	0.000356	0.00131	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000354	0.0013	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00034	0.00125	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	0.00034	0.00125	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000337	0.00124	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PTH—nephrolithiasis	0.00033	0.00121	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	0.000329	0.00121	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PTH—nephrolithiasis	0.000323	0.00119	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.00031	0.00114	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.0003	0.0011	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000294	0.00108	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DGKH—nephrolithiasis	0.000294	0.00108	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	0.000294	0.00108	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000294	0.00108	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000289	0.00106	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DGKH—nephrolithiasis	0.000289	0.00106	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000276	0.00101	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000255	0.000937	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000255	0.000937	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000246	0.000902	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000235	0.000862	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000235	0.000862	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTH—nephrolithiasis	0.000225	0.000825	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CHRM3—nephrolithiasis	0.000213	0.000782	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	0.000212	0.000779	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000209	0.000767	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000203	0.000744	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTH—nephrolithiasis	0.000195	0.000715	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTH—nephrolithiasis	0.000194	0.000713	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTH—nephrolithiasis	0.000191	0.000702	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.000182	0.000668	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000181	0.000663	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000167	0.000614	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000164	0.000604	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000153	0.000564	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000153	0.000564	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000151	0.000555	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	0.000113	0.000414	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AQP1—nephrolithiasis	0.000109	0.000402	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CHRM3—nephrolithiasis	9.89e-05	0.000363	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SPP1—nephrolithiasis	9.78e-05	0.000359	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	9.74e-05	0.000358	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SPP1—nephrolithiasis	9.59e-05	0.000352	CbGpPWpGaD
